Alunbrig (brigatinib) — United Healthcare
symptomatic Erdheim-Chester Disease (ECD)
Initial criteria
- Diagnosis of symptomatic Erdheim-Chester Disease
- Used as targeted therapy ALK-fusion
- Disease is relapsed OR refractory
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Alunbrig therapy
Approval duration
12 months